Biosyent Inc. · TSXV:RX
Biosyent — Q3 2022 Earnings Presentation
15 slides from Biosyent's earnings presentation, Nov 16, 2022
Slide 1: BioSyent Inc. Q3 / YTD 2022 Results
BioSyent Inc. Q3 / YTD 2022 Results NOVEMBER 16, 2022 PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: Sales, EBITDA and NIAT - Quarter ended September 30, 2022
Sales, EBITDA and NIAT Quarter (Q3) ended September 30, 2022 7,000 +16% +2% Q3 2022 Sales: 6,000 -7% -1%* Canadian Pharma 0% International Pharma 5,000 +49% Legacy *+7% on Continuing Canadian 4,000 Pharma Brands (excluding brands CAD (000's) discontinued in Jan 2022) 3,000 +64% -15% 2,000 +80% 49 Co
Slide 4: Sales, EBITDA and NIAT - Nine Months ended September 30, 2022
Sales, EBITDA and NIAT Nine Months (YTD) ended September 30, 2022 +29% -4% 20,000 YTD 2022 Sales: -2%* Canadian Pharma +5% -57% International Pharma +20% Legacy 15,000 *+4% on Continuing Canadian CAD (000's) Pharma Brands (excluding brands 10,000 discontinued in Jan 2022) +38% -5% +10% +41% -3% 5,00
Slide 5: Fully Diluted Earnings per Share
Fully Diluted Earnings per Share Quarter NIAT Diluted EPS Q3 2022 $1,453,042 $0.12 Q2 2022 $1,217,883 $0.10 $0.49 Q1 2022 $1,587,904 $0.13 Q4 2021 $1,877,804 $0.15 Q3 2021 $1,721,320 $0.13 Q2 2021 $1,018,074 $0.08 $0.39 Q1 2021 $1,664,368 $0.13 Q4 2020 $665,702 $0.05 5 | www.biosyent.com | TSXV: RX
Slide 6: Q3 / YTD 2022 Sales Summary
Q3 / YTD 2022 Sales Summary Q3 ‘22 Q3 ‘22 vs. YTD ‘22 YTD ‘22 vs. Sales ($) Q3 ’21 (%) Sales ($) YTD ’21 (%) Canadian Pharma ($) $6,372k (1%) $18,963k (2%) FeraMAX® (units) +6% +1% Continued growth from RepaGyn® (units) +13% +14% established brands YTD Cathejell® (units) (1%) +4% 2022 Tibella® (unit
Slide 7: Most recommended iron supplement in Canada
▪ Most recommended iron supplement in Canada - pharmacists and physicians - 7 consecutive years(1) ▪ Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2022 Survey on OTC Counselling and Recomme
Slide 8: A New Platform for FeraMAX Product Innovation
A New Platform for FeraMAX® Product Innovation ▪ FeraMAX® Pd platform introduced in October 2020 ▪ Patented delivery system based on Polydextrose Iron Complex (“PDIC”) ▪ Foundation for future product development ▪ FeraMAX® Pd Therapeutic 150 launched Nov 2020 ▪ FeraMAX® Pd Powder 15 launched Oct 202
Slide 9: Growth Drivers
Growth Drivers Investments In: FeraMAX® Pd Platform – Life Cycle Strategy • New product 2023 Field Salesforce • Additional products in development HRT agent for menopause therapy • Launched July 2020 Marketing Resources First formulation combining acetaminophen + ibuprofen for pain relief in Canada
Slide 10: Cash Balance & Return on Equity (RoE)
Cash Balance & Return and Equity (“RoE”) 30,000 20% • Zero Debt 19% 19% 28,000 27,785 • TTM Sept 30/22 NCIB share 27,102 19% buybacks: $3.7M 26,000 18% 18% • Sept 30/22 Working Capital 24,000 of $31.3M CAD (000's) RoE % 23,702 18% 22,000 17% • TTM Sept 30/22 Cash from 17% Operations of $4.7M 20,000
Slide 11: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue growth & portfolio diversification Cash: Dividends $27.8M Growth & Diversification Debt: Share $0M Buybacks Excess capital may also be returned to shareholders • $0.04/share Q4 2022 dividend declared Oct 12, 2022 = $0.
Slide 12: Normal Course Issuer Bid (NCIB)
Normal Course Issuer Bid (NCIB) Fully Diluted No. Shares Shares Period Repurchased Outstanding Dec 10, 2018 14,675,307 420,800 shares NCIB Purchases: Dec 10, 2018 – present (2,196,725) purchased Jan 1 – Nov 14, As of November 14, 2022 12,508,806 2022 ▪15% reduction in f/d shares since commencing NCI
Slide 13: Stock Information
Stock Information As at November 14, 2022 Exchange & Trading Symbol 0% TSXV: RX November 14, 2022 Closing Stock Price (CAD) $7.03 52 Week Hi/Low: $10.00 / $6.24 Issued Common Shares: 12,343,061 Treasury – RSU Shares in Trust (241,300) Outstanding Common Shares: 12,101,761 Options Outstanding 164,295
Slide 14: Profitable. Well Positioned. Growth Assets.
PROFITABLE. WELL POSITIONED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 14 | www.biosyent.com | TSXV: RX
Slide 15: Thank You
THANK YOU 2476 Argentia Road, Suite 402 +1 905 206 0013 investors@biosyent.com www.biosyent.com Mississauga ON L5N 6M1 Canada 15 | www.biosyent.com | TSXV: RX